Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this research is to determine whether the use of phototherapy can help reduce behavioral and psychological symptoms, including agitation in people with dementia.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Phototherapy | Experimental | Patients in the phototherapy arm will receive bright light therapy for 60 minutes, 3 times per day for 5 days. |
|
| Standard of Care | No Intervention | Patients in the standard of care group will not receive an intervention. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Phototherapy | Other | Bright light therapy will be provided via the Verilux HappyLight. The unit will be placed on a mobile bedside table, at eye level, 60 cm from the patient. Patients will receive phototherapy in 60 minute sessions, 3 times daily for 5 days. |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility of 5-day phototherapy protocol | Feasibility will be defined as the percentage of eligible patients who choose to enroll in the study out of total patients approached. | Day 5 |
| Acceptability of 5-day phototherapy protocol | Accessibility will be defined as the percentage of study participants to complete at least one session per day of the 5-day protocol | Day 5 |
| Tolerability of 5-day phototherapy protocol | Tolerability will be defined as percentage of patients to rate phototherapy as 'very tolerable' based on being asked "Considering all aspects of your experience, how would you rate the overall tolerability of the phototherapy?" The response options are: very tolerable, somewhat tolerable, neutral, somewhat intolerable, and very intolerable. | Day 5 |
| Measure | Description | Time Frame |
|---|---|---|
| Sleep duration | Sleep duration will be reported by nursing staff in hours. | Day 5 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Melanie Gentry, MD | Contact | 507-284-2933 | gentry.melanie@mayo.edu | |
| Donna Lawson | Contact | 507-255-7975 | lawson.donna@mayo.edu |
| Name | Affiliation | Role |
|---|---|---|
| Stephanie P. Chambers, APRN, CNS | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | United States |
Not provided
| Label | URL |
|---|---|
| Mayo Clinic Clinical Trials | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003704 | Dementia |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D019965 | Neurocognitive Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D010789 | Phototherapy |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D001523 | Mental Disorders |